ClinicalTrials.gg
CompletedNCT02072161Updated Mar 29, 2019

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

A Phase 2 interventional study of ETC-1002 and Placebo in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 40 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
10th of 21
133 · median 126
Started
2014
with 1 other
Phase 2
10 of 21
none open now
Registered
4th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 4th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.

Read the detailed description

Approximately 132 hypercholesterolemic patients already taking statin therapy to treat elevated LDL-C will be randomized in a ratio of 1:1:1 to receive either ETC-1002 (120 mg or 180 mg dose), or placebo for 12 weeks in addition to ongoing statin therapy. This study will explore the safety and efficacy of ETC-1002 when given to patients receiving statin therapy.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Statin
  • LDL
  • Cholesterol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting, calculated mean LDL-C ≥130 mg/dL and ≤220 mg/dL
  • Fasting mean TG level ≤400 mg/dL
  • Stable statin therapy for at least 3 months prior to screening: atorvastatin (10 or 20 mg daily), simvastatin (5, 10 or 20 mg daily), rosuvastatin (5 or 10 mg daily), or pravastatin (10, 20 or 40 mg daily)

Exclusion criteria

Exclusion Criteria:

  • cardiovascular disease within 12 months of screening
  • Current muscle-related symptoms that may be due to ongoing statin therapy or a history of certain lab abnormalities that occurred during statin therapy and resolved when statin therapy was discontinued
  • Type 1 diabetes or uncontrolled type 2 diabetes
  • Use of metformin or thiazolidinediones (TZD) within 4 weeks of screening
  • History of chronic musculoskeletal symptoms such as fibromyalgia
  • Uncontrolled hypothyroidism
  • Liver disease or dysfunction
  • Renal dysfunction or nephritic syndrome
  • Gastrointestinal conditions or procedures or surgeries
  • Hematologic or coagulation disorders or low levels
  • or AIDS
  • History of
  • History of drug or alcohol abuse within 2 years
  • Use of experimental or drugs within 30 days of screening
  • Use of ETC-1002 in a previous clinical study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    ETC-1002 120 mg/day

    Orally, once daily in morning as capsules

    Drug: ETC-1002 · Drug: Statin Therapy

  • Experimental
    ETC-1002 180 mg/day

    Orally, once daily in morning as capsules

    Drug: ETC-1002 · Drug: Statin Therapy

  • Placebo comparator
    Placebo

    Orally, once daily in morning

    Drug: Placebo · Drug: Statin Therapy

Interventions

  • ETC-1002 capsules, taken once daily oral

  • DrugPlacebo

    Placebo capsules, taken once daily oral

  • Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in calculated low density lipoprotein-cholesterol (LDL-C)

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)

    Time frame: 12 weeks

  2. Percent change in apolipoprotein B (ApoB)

    Time frame: 12 weeks

  3. Percent change in total cholesterol (TC)

    Time frame: 12 weeks

  4. Percent change in high-sensitivity C-reactive protein (hsCRP)

    Time frame: 12 weeks

  5. Percent change in triglycerides (TG)

    Time frame: 12 weeks

  6. Percent change in lipoprotein particle number

    Time frame: 12 weeks

  7. Safety using adverse event reports; clinical laboratory results

    Time frame: 12 weeks

  8. Safety using adverse event reports; vital signs

    Time frame: 12 weeks

  9. Pharmacokinetic plasma trough concentrations of ETC-1002 and metabolite 15228

    Time frame: 12 weeks

07

Study locations

40 sites
  • Muscle Shoals, Alabama 35662, United States
  • Chandler, Arizona 85224, United States
  • Chino, California 91710, United States
  • Los Angeles, California 90057, United States
  • Sacramento, California 95821, United States
  • Walnut Creek, California 94595, United States
  • Denver, Colorado 80220, United States
  • Hartford, Connecticut 06102, United States
  • Brandon, Florida 33511, United States
  • Jacksonville, Florida 32216, United States
  • Oviedo, Florida 32765, United States
  • Ponte Vedra, Florida 32081, United States
  • Tampa, Florida 33606, United States
  • West Palm Beach, Florida 33409, United States
  • Marietta, Georgia 30066, United States
  • Boise, Idaho 83704, United States
  • Meridian, Idaho 83646, United States
  • Evansville, Indiana 47714, United States
  • Indianapolis, Indiana 46260, United States
  • Wichita, Kansas 67205, United States
  • Louisville, Kentucky 40213, United States
  • Port Gibson, Mississippi 39150, United States
  • Rochester, New York 14609, United States
  • Salisbury, North Carolina 28144, United States
  • Cincinnati, Ohio 45219, United States
  • Cincinnati, Ohio 45245, United States
  • Columbus, Ohio 43213, United States
  • Franklin, Ohio 45005, United States
  • Lyndhurst, Ohio 44124, United States
  • Marion, Ohio 43302, United States
  • Tulsa, Oklahoma 74136, United States
  • Greer, South Carolina 29651, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Summerville, South Carolina 29485, United States
  • Kingsport, Tennessee 37660, United States
  • Houston, Texas 77030, United States
  • Bountiful, Utah 84010, United States
  • Orem, Utah 84058, United States
  • Norfolk, Virginia 23502, United States
  • Richmond, Virginia 23294, United States
08

References and documents

Publications

  • Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2. PubMed 24385236 ↗
  • Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13. PubMed 23770179 ↗
  • Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, Srivastava RAK, Hurley TR, Bradshaw CD, Spahr MA, Newton RS. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095-2108. doi: 10.1194/jlr.M035212. Epub 2013 May 24. PubMed 23709692 ↗
  • Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134-51. doi: 10.1194/jlr.M030528. Epub 2012 Nov 1. PubMed 23118444 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2014
First posted
Feb 26, 2014
Start
Mar 2014
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results delay requested
Aug 13, 2015
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02072161
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Mar 2014
Primary completion
Jan 2015
Completion
Jan 2015
Last update
Mar 29, 2019

Study contacts

Diane E MacDougall
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion